Novo Nordisk A/S (NVO · NYSE)
NVO · MARKET VIEW
Market view · as of Jul 20, 2026
Revenue (TTM)
$327.80B
+24.0% YoY
Gross margin
83.2%
EPS (latest q)
$6.63
vs $6.96 est · miss
52-wk position
45.9%
-26.6% vs 52w high · +15.6% 1mo
Price (last ~year)
Novo Nordisk recently secured European Commission approval for its oral Wegovy pill, marking the first GLP-1 receptor agonist in pill form cleared for weight management in the region. The company reported 24.0% year-over-year revenue growth and 67.1% earnings growth, supported by an 83.2% gross margin and 61.6% operating margin. Shares are trading at $50.32, reflecting a 27.7% increase over the last three months, against a market capitalization of $222.61B.
Valuation
- Market cap
- $222.61B
- P/E
- 12.07
- PEG
- 3.715
- P/B
- 7.21
- P/S
- 4.493
- EV/EBITDA
- 8.81
- Beta
- 0.36
- Analyst target
- $47.57
Quality & returns
- Gross margin
- 83.2%
- Operating margin
- 61.6%
- Profit margin
- 37.2%
- ROE
- 71.4%
- ROA
- 19.3%
Price movement
- Last
- $50.32
- 1-month
- +15.6%
- 3-month
- +27.7%
- RSI (14)
- 61
- vs SMA200
- +8.5%
- 52-wk position
- 45.9% -26.6% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-03-31 | $96.82B | $59.62B | $48.56B | $69.21B |
| 2025-12-31 | $79.14B | $31.74B | $26.89B | $39.75B |
| 2025-09-30 | $74.98B | $23.68B | $20.01B | $33.27B |
| 2025-06-30 | $76.86B | $33.45B | $26.50B | $43.60B |
Recent news
- Neutral Novo Nordisk: EU Approval of Wegovy Pill Expands Opportunity, but Cash Pay Raises Systematic Risk · 2026-07-17
- Somewhat-Bullish Novo Nordisk (NYSE:NVO) Wins First EU Approval For Oral Wegovy In Weight Management · 2026-07-16
- Bullish Novo secures European approval for oral Wegovy to extend lead over Lilly · 2026-07-16
- Somewhat-Bullish Novo's Wegovy pill cleared for weight loss in EU · 2026-07-16
- Bullish Novo Nordisk Expands Cardiometabolic Reach With New Heart Failure–Obesity Trial · 2026-07-15
- Somewhat-Bullish Novo gains head start on Lilly with European Commission approval of Wegovy pill · 2026-07-15
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)